NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · SMALL CAP
aTYR Pharma Inc. ATYR
13 fiscal years on record · USD · FY2025 reported · SEC filings only
Growth
USD 190,000.00
Revenue, FY2025 · full 13-year series below
Revenue $M
Net income $M
FY2025 · Revenue 0.2 · Net income -74.1
Compound annual growth
Revenue compounded at −55.1% a year over five years.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
−39012 cents
lost on every revenue dollar
Operating margin
Net margin
FY2025 · Operating -40856.3% · Net -39012.1%
ROE
FY2025 · ROE -107.8%
Each USD of equity lost 108 cents this year.
The 13-year record
13 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · | · | · | · | · | · |
| Operating income $B | −0.1 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.1 | −0.0 | −0.0 | −0.0 |
| EBITDA $B | −0.1 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.1 | −0.0 | −0.0 | −0.0 |
| Income tax $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · | −0.0 | · | · | · |
| Net income $B | −0.1 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.1 | −0.0 | −0.0 | −0.0 |
| Free cash flow $B | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.1 | −0.0 | −0.0 | −0.0 |
| EPS, diluted $ | −0.80 | −0.86 | −0.94 | −1.60 | −1.77 | −1.77 | −7.03 | −16.11 | −26.13 | −2.44 | −3.03 | −29.69 | −28.39 |
| Dividend / sh $ | · | · | · | · | · | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · | · | · | · | · | · |
| ROE % | −107.8 | −79.7 | −62.2 | −50.2 | −47.9 | −61.4 | −59.2 | −70.5 | −75.9 | −65.1 | −399.1 | · | · |
| Shares out B | 0.10 | 0.08 | 0.06 | 0.03 | 0.03 | 0.01 | 0.00 | 0.00 | 0.03 | 0.02 | 0.02 | 0.00 | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 50 reconciliationsAUDITED
Reconciled in 13 of 19 fiscal years. 26 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityBiological Products, (No Diagnostic Substances)
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2013